HealthFlex
×
  • Home
  • For Patients
    • What is an ERN?
    • Understand your Diagnosis
    • News for Patients
    • Meetings & Events
    • Support Groups
      • Find a Health Care Professional
      • Contact
    • Cross-border Healthcare
  • Our Network
  • ERN Expertise
    • Rare Diseases Subnetworks
    • Transversal Activities
    • Work Packages
    • Patient Board
  • Media
    • Informative Materials
  • What's New
    • News
    • News for Patients
    • Meetings & Conferences
    • Newsletter
  • ERNs
  • Links
  • Contact
  • Privacy Policy
FRANCJAN VAN SPRONSEN

Francjan J van Spronsen, Full Prof in Pediatrics Head of the Division of Metabolic Diseases in the Beatrix Children’s Hospital of the University Medical Center of Groningen He is a Principal Investigator in the UMCG and coordinator of the nationally endorsed UMCG centers of expertise called “PKU and Tyrosinemia type I’ and has started the process for national endorsement for ‘very rare metabolic diseases’ as an umbrella center of expertise for very rare diseases such as Molybdenum Cofactor Deficiency.

FRANCJAN VAN SPRONSEN

Full prof in Pediatrics UNIVERSITY OF GRONINGEN, UNIVERSITY MEDICAL CENTER GRONINGEN, BEATRIX CHILDRENS’HOSPITAL, SECTION OF METABOLIC DISEASES, GRONINGEN, THE NETHERLANDS

Francjan van Spronsen is a pediatrician in metabolic diseases at the Beatrix Children’s Hospital, University Medical Centre of Groningen (UMCG.
Francjan van Spronsen was appointed as full professor in pediatrics with special interest in defects in amino acid metabolism at the University of Groningen, and is in charge of the Division of Metabolic Diseases in the Children’s Hospital of the UMCG. He currently treats patients with metabolic diseases from birth into (late) adulthood. Before that he was trained to become a MD, after which he joined already the metabolic diseases Division combining PhD research on PKU and Tyrosinemia type I with clinical work. He was later trained to become a general pediatrician and served as pediatrician various children’s clinics for various chronic diseases as well as being a supervisor of a clinical ward for general pediatrics.
His present research focus is on the causes and consequences of defects in amino acid metabolism in both basic research with in-vitro and animal studies and the relationships between metabolic control, patient’s disease severity and quality of dietary management and outcomes (both neurocognitive, neuropsychological and social), and the improvement of these abnormalities, resulting in some 170 papers of which some 100 on PKU or Tyrosinemia type I only.
At the university level he has served and serves in various coordinating roles for education programs and has been chairing the Exam Committee for MDs and now is chairing the committee to judge the applications for MDs to enter the UMCG MD/PhD program that offers MD students the possibility to perform 2-3 years of research time to also obtain a PhD degree in addition to their MD degree.
At a national level, he chairs the Advisory Committee on Neonatal Screening with respect to inherited metabolic diseases, and is a member of the Dutch Committee on Neonatal Screening. At an international level, he chairs the Scientific Advisory Board of the European Society of PKU and Allied Disorders, and is a member of various European and international advisory boards and working groups for various defects in amino acid metabolism. Together with Prof Dr Stefan Koelker and Prof dr Henk Blom, he is co-ordinator of the MetabERN subnetwork of ‘Amino acid and Organic Acidurias’.
Francjan van Spronsen was in the lead of 19 European PKU experts who just published their first papers on the first ever European guidelines for PKU in the Lancet Diabetes & Endocrinology and Metabolism, and the Orphan Journal of Rare Diseases.

logo

For more information please contact
Prof. Maurizio Scarpa, MD, PhD
MetabERN Coordinator

MetabERN is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Commission. For more information about the ERNs and the EU health strategy, please visit ec.europa.eu/health/ern

Follow us on Twitter

Tweets by @Metab_ERN

MetabERN

  • Home
  • For Patients
    • What is an ERN?
    • Understand your Diagnosis
    • News for Patients
    • Meetings & Events
    • Support Groups
      • Find a Health Care Professional
      • Contact
    • Cross-border Healthcare
  • Our Network
  • ERN Expertise
    • Rare Diseases Subnetworks
    • Transversal Activities
    • Work Packages
    • Patient Board
  • Media
    • Informative Materials
  • What’s New
    • News
    • News for Patients
    • Meetings & Conferences
    • Newsletter
  • ERNs
  • Links
  • Contact
  • Privacy Policy

Copyright ©2017-2019 all rights reserved
Web by EFFIGE 2.0
To provide the best possible service, we use technical, statistical and third-party cookies on this site. Continuing the navigation you consent to use them. Accept Reject Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.